Aktienanalyse zu Kenvue Inc (KVUE)KVUEKenvue Inc

Kenvue Inc. is a consumer health company. The Company's differentiated portfolio of brands includes Aveeno, BAND-AID Brand, Johnson's, Listerine, Neutrogena, Nicorette, Tylenol, and Zyrtec. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee's, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women's health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM). It operates in the Consumer Non-Cyclicals sector (PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS industry).

Kenvue Inc is a good buy right now due to its current price of $17.7 being below the analyst price target of $19, indicating potential upside. Additionally, the forward P/E ratio of 14.73 suggests the stock is reasonably valued compared to its earnings potential. However, the main risk is the RSI at 55.20, which indicates it is approaching overbought territory, suggesting caution may be warranted in the short term.

1 analysts cover KVUE: 0 rate it Buy, 0 Hold and 1 Sell. The average price target is 18.86.